NEW YORK – NRG1 gene fusions, rare alterations found most commonly in lung and pancreatic cancers, have attracted the attention of several drugmakers as a new indication for precision oncology therapeutics worthy of pursuit.
Startup Elevation Oncology and drug developer Merus both announced this month they were advancing cancer drugs targeting NRG1 fusions.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try Premium Access now.
You may already have institutional access!
Check if I qualify.
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.